AcrySof Natural Lens
Shreveport Cataract Surgery Breakthrough in Cataract Surgery Approximates Eye’s Natural Blue Light Filtering Capability
New AcrySof® Natural IOL from Alcon First to Address Potential AMD Risk Factors
Shreveport, Louisiana, February 7, 2005 – A revolutionary advance in Shreveport cataract surgery is now available in the United States following approval by the U.S. Food and Drug Administration (FDA). Dr. James Lusk of Lusk Eye Specialists is now using AcrySof® Natural IOL, the world’s first foldable intraocular lens (IOL) that is specifically designed to filter high-energy wavelengths of the blue light spectrum, for Shreveport cataract surgery patients.
When a cataract is removed, an artificial intraocular lens is inserted. Until the availability of the AcrySof Natural Lens, IOLS were less effective than the eye’s natural ability to filter blue light. The new AcrySof Natural IOL approximates the natural blue light filtering capability of the human lens.
“A growing body of evidence shows high frequency blue light may lead to retinal damage,” said Dr. Lusk. “The AcrySof Natural IOL filters this potentially dangerous blue light without negative visual consequences.
“I Age-Related Macular Degeneration (AMD) is a degeneration of the macula, the eye’s most light- sensitive region of the retina, The disease impacts central vision and may limit the ability to read, drive and perform other activities that require fine, sharp vision.
Research suggests blue light may be one of the risk factors in causing the progression of AMD. AMD is one of the leading causes of blindness in the developed world. However, the long-term effects of filtering blue light and the clinical efficacy of that filtering on the retina have not been conclusively established.
“With this new intraocular lens, we are able to offer patients the improved quality of life afforded by cataract surgery, plus the potential benefit of filtering blue light,” Dr. Lusk said. “This is an important advance for patients undergoing cataract surgery.”
In addition to an ultraviolet (UV) light-absorbing chromophore, the AcrySof® Natural lens features a patented yellow chromophore that is integrated into the lens material to filter high-energy wavelengths of the blue light spectrum. Results from the clinical study show while the lens provides increased blue-light filtration, it does not alter color perception, or the ability to see under dim light conditions.
The yellowing of the human crystalline lens as we age may offer protection against ultraviolet and blue light waves damaging the macula. The AcrySof Natural lens replaces both the UV and blue light filtering characteristics of the crystalline lens that are lost following cataract surgery.
“The AcrySof Natural IOL has been rapidly gaining adoption in many international markets where it already has been launched,” said Cary Rayment, Senior Vice President, Alcon United States, “We believe many ophthalmic surgeons in the U.S. also will be interested in the unique capability of the AcrySof Natural IOL to filter high-energy wavelengths of the blue light spectrum, and they will begin adopting this innovative technology for their patients
Shreveport Lens Implants Facts about AcrySof:
AcrySof® Natural IOL is a revolutionary advance for cataract patients. It is the world’s first foldable intraocular lens (IOL) for cataract surgery that is specifically designed to filter both ultraviolet (UV) and high-energy wavelengths of the blue light spectrum. Shreveport cataract surgery patients can now benefit from one of the most advanced IOL implants in the world,
Replaces a clouded cataractous human crystalline lens through cataract surgery to help improve patients quality of life through clarity of vision. Approximates the eye’s natural filtration of potentially damaging blue light. Until the availability of AcrySof® Natural IOL, blue light filtration was lost following cataract surgery. Studies show blue light may be one of the risk factors in Age-Related Macular Degeneration (AMD). AMD is one of the leading causes of blindness in the developed world. The long-term effects of filtering blue light and the clinical efficacy of that filtering on the retina have not been conclusively established.
AcrySof® Natural is a foldable, single-piece IOL designed to enable suture-less surgery through a smaller incision than required by non-foldable IOLS. Utilizes the same patented base material, with the addition of a blue-light filtering chromophore, as the original AcrySof® IOL. The AcrySof® base material was developed specifically for use as an intraocular lens. Since 1994, more than 16 million AcrySof® lenses have been implanted globally. A proprietary yellow chromophore is covalently bonded with the implant material to safely and effectively filter high-energy wavelengths of the blue light spectrum. Results from the clinical study show while the lens provides increased blue-light filtration, it does not alter color perception, or the ability to see under dim light conditions. Incorporates the UV light-absorbing chromophore found in earlier AcrySofe® brand IOL products.
Gained rapid adoption in many international markets since introduction in September 2002. U.S. Food and Drug Administration (FDA) approval granted in June 2003. Became available to U.S. ophthalmologists in August 2003. Taylor, HR, West S, Munoz B, Rosenthal FS, Bressler NM. The Long-Term Effects of Visible Light on the Eye. Arch Ophthalmol 1992; 99-104. Beatty S. Koh HH, Henson D, Boulton M. The Role of Oxidative Stress in the Pathogenesis of Age- Related Macular Degeneration. Surv Ophthalmol 2000; 45: 115-134.